UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $758.49 Million Holdings in DexCom, Inc. $DXCM

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 15.6% in the second quarter, HoldingsChannel reports. The fund owned 11,261,876 shares of the medical device company’s stock after acquiring an additional 1,515,702 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in DexCom were worth $758,487,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in DXCM. Geode Capital Management LLC increased its stake in shares of DexCom by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock worth $727,842,000 after purchasing an additional 42,411 shares during the period. Norges Bank bought a new stake in DexCom in the 4th quarter valued at $483,356,000. Invesco Ltd. boosted its stake in DexCom by 14.8% in the 4th quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock valued at $352,781,000 after purchasing an additional 686,228 shares during the period. CIBC Private Wealth Group LLC boosted its stake in DexCom by 7.6% in the 4th quarter. CIBC Private Wealth Group LLC now owns 3,128,114 shares of the medical device company’s stock valued at $207,613,000 after purchasing an additional 220,313 shares during the period. Finally, AQR Capital Management LLC grew its holdings in DexCom by 597.8% in the 4th quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock valued at $205,932,000 after buying an additional 2,658,158 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Up 1.7%

DXCM stock opened at $90.82 on Friday. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59. The business has a 50-day simple moving average of $79.21 and a 200 day simple moving average of $71.60. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The company has a market cap of $34.27 billion, a PE ratio of 35.90, a price-to-earnings-growth ratio of 1.53 and a beta of 1.41.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. During the same period in the prior year, the company posted $0.48 earnings per share. The business’s revenue for the quarter was up 13.1% on a year-over-year basis. Sell-side analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Insider Activity at DexCom

In related news, insider Kevin R. Sayer sold 26,756 shares of the stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the sale, the insider owned 328,970 shares in the company, valued at approximately $25,106,990.40. This trade represents a 7.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Sadie Stern sold 2,565 shares of DexCom stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $88.37, for a total transaction of $226,669.05. Following the completion of the transaction, the executive vice president directly owned 126,043 shares in the company, valued at $11,138,419.91. This trade represents a 1.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 75,600 shares of company stock worth $5,673,342 in the last 90 days. Corporate insiders own 0.28% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Argus increased their price objective on DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Royal Bank Of Canada boosted their target price on shares of DexCom from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. TD Cowen restated a “buy” rating on shares of DexCom in a research note on Friday, July 31st. Stifel Nicolaus set a $95.00 price target on shares of DexCom and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Wall Street Zen cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $88.71.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.